PF-05280586

Biologic (subtype unspecified)

Biosimilar of Rituximab

Approvedregulatory verdict

Evidence outlook

Approved: Rheumatoid Arthritis, Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Large B-Cell Lymphoma, Relapsed/Refractory Non-Hodgkin Lymphoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (3)
US
  • Granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis) and microscopic polyangiitis (MPA) in adults, in combination with glucocorticoids
  • Moderate to severe pemphigus vulgaris (PV) in adults
Product first approved 2019Outside this platform's coverageFDA label
EU
  • Ruxience (rituximab): NHL, CLL, rheumatoid arthritis, GPA/MPA, pemphigus vulgaris
Product first approved 2020EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Phase 2 (1)
Early phase / not applicable (1)
Rheumatoid Arthritis
NCT01643928 · Pfizer
2012-08-16 – 2016-03-14 · Rheumatoid Arthritis
What this study did

Competitive landscape

This mechanism is crowded: 15 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Follicular Lymphoma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
PF-05280586: this drugApprovedBiologic (subtype unspecified)CD20Reliable signal
NCT02213263: Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26 (Week 26): Rituximab-EU 70.7 percentage of participants (95% CI 63.8 to 76.9) | PF-05280586 75.5 percentage of participants (95% CI 68.9 to 81.4)
EpcoritamabApprovedMultispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
Interferon Alfa-2b (Intron A)ApprovedBiologic (subtype unspecified)Type I interferon receptornot yet gradedNo reviewed efficacy summary in this indication
LenalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligase, Thalidomide Analognot yet gradedNo reviewed efficacy summary in this indication
ObinutuzumabApprovedMonoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
Ocrelizumab
Approved(overall)
Monoclonal antibodyCD20
Reliable signal(overall)
No reviewed efficacy summary in this indication
Ocrevus Zunovo
Approved(overall)
Monoclonal antibodyCD20
not yet graded(overall)
No reviewed efficacy summary in this indication
Ofatumumab
Approved(overall)
Monoclonal antibodyCD20
Reliable signal(overall)
No reviewed efficacy summary in this indication
Rituximab (Rituxan)ApprovedMonoclonal antibodyCD20, CD20-directed Cytolytic Antibodynot yet gradedNo reviewed efficacy summary in this indication
TafasitamabApprovedMonoclonal antibodyCD19Reliable signalNo reviewed efficacy summary in this indication
Ublituximab (Briumvi)
Approved(overall)
Monoclonal antibodyCD20
Reliable signal(overall)
No reviewed efficacy summary in this indication
Zanubrutinib (Brukinsa)ApprovedSmall moleculeBTKnot yet gradedNo reviewed efficacy summary in this indication
ABP 692
Phase 3(overall)
Monoclonal antibodyCD20
not yet graded(overall)
No reviewed efficacy summary in this indication
BCD-281
Phase 3(overall)
Monoclonal antibodyCD20
not yet graded(overall)
No reviewed efficacy summary in this indication
CT-P53
Phase 3(overall)
Monoclonal antibodyCD20
not yet graded(overall)
No reviewed efficacy summary in this indication
Divozilimab (Ivlizi)
Phase 3(overall)
Monoclonal antibodyCD20
Reliable signal(overall)
No reviewed efficacy summary in this indication
Obinutuzumab Beta (Bejescin)Phase 3Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
OdronextamabPhase 3Multispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
SurovatamigPhase 3Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
Zugocabtagene GeleucelPhase 1/2Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.